CDKN2B对于维拉帕米介导的肝癌多柔比星耐药逆转至关重要。

CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma.

作者信息

Zhang Tengyue, Ma Kelong, Huang Jin, Wang Shitang, Liu Yabei, Fan Gaofei, Liu Miao, Yang Guangshan, Wang Cheng, Fan Pingsheng

机构信息

School of Clinical Medicine, Shan Dong University, Jinan 250100, China.

The Cancer Hospital of Anhui Province, Provincial Hospital of Anhui Medical University, Hefei 230032, China.

出版信息

Oncotarget. 2017 Oct 26;8(66):110052-110063. doi: 10.18632/oncotarget.22123. eCollection 2017 Dec 15.

In this study, we explored the function and mechanism of CDKN2B genes in verapamil (VER)-induced reversal of resistance to doxorubicin (ADM) chemotherapy in hepatocellular carcinoma (HCC). We examined 4 HCC cell lines and found that the expression levels of CDKN2B genes correlated with the level of apoptosis induced by ADM+VER. Overexpression of CDKN2B genes promoted apoptosis in cells treated with VER+ADM. CDKN2B knockdown using siRNA weakened the effect of ADM+VER, indicating that ADM+VER promotes HCC cell apoptosis and that CDKN2B genes participate in VER-mediated promotion in tumor cell apoptosis. Future research will further explore the functional mechanism, and the associated signal transduction pathways via which CDKN2B affects HCC drug resistance.